Mymetics (Mymetics) Treasury Stock : $0.00 Mil (As of Sep. 2023)

View and export this data going back to 1995. Start your Free Trial

What is Mymetics Treasury Stock?

Treasury stock is the portion of shares that a company keeps in their own treasury. Mymetics's treasury stock for the quarter that ended in Sep. 2023 was $0.00 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.

Mymetics Treasury Stock Historical Data

The historical data trend for Mymetics's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mymetics Treasury Stock Chart

Mymetics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Treasury Stock

Get a 7-Day Free Trial

Mymetics Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Treasury Stock	Get a 7-Day Free Trial															-	-	-	-	-

Mymetics Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.

Mymetics (Mymetics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mymetics Corp (OTCPK:MYMX) » Definitions » Treasury Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

c/o Mymetics SA, Route de la Corniche 4, Biopole Center, Epalinges, CHE, CH-1066

Website

https://www.mymetics.com

Mymetics Corp is a vaccine company and is focused on the research and development of next-generation vaccines for infectious and life-disabling diseases. Its vaccine candidates in the pipeline include HIV-1/AIDS, malaria, and Covid-19, and intranasal influenza, RSV, Chikungunyaand HSV vaccine candidate programs.

Executives

Marcel B. Ruegg	director	C/O MYMETICS CORPORATION, ROUTE DE LA CORNICHE 4 1066, EPALINGES V8 NA
Kempers Ronald Hugo Gerard	officer: President, CEO, CFO	ES GRANDS CHAMPS 12, DULLY V8 1195
Christopher S Henney	director	10505 ROSELLE STREET, SAN DIEGO CA 92121
Grant Pickering	director, officer: President and CEO	C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070
Ulrich Burkhard	director	C/O MYMETICS CORPORATION, ROUTE DE LA CORNICHE 4 1066, EPALINGES V8 NA
Jacques Francois Martin	officer: CEO	40 QUAI FULCHIRON, LYON I0 69005
Antonius Johannes Stegmann	officer: CSO	KONINGIN EMMAPLANTSOEN 6, RIJNSBURG P7 2231TZ
Ernest M Stern	director	815 CONNECTICUT AVE, NW, SUITE 500, SEYFARTH SHAW LLP, WASHINGTON DC 20006
Thomas Staehelin	director	POSTFACH 2879, FROMER, SCHULTHEISS & STAEHELIN, BASEL V8 CH-4002
Sylvain Fleury	officer: CSO	CHEMIN DE VERDONNET 9, LAUSANNE V8 1010
Round Enterprises, Ltd.	10 percent owner	C/O BACHMANN TRUST COMPANY LIMITED, FRANCES HOUSE, SIR WILLIAM PLACE, ST. PETER PORT X0 GY1 4EA
Mfc Bancorp Ltd	10 percent owner	ROOM 2103 SHANGHAI MART TOWER, 2299 YAN AN ROAD WEST, CHANGNING DISTRICT, SHANGHAI F4 200336
Christian Rochet	director, officer: CEO	14, RUE DE LA COLOMBIERE, NYON V8 1260
Robert Zimmer	director, officer: vp corp development
Ernst Lubke	director, officer: CFO	39, ROUTE D'ARZIER, ARZIER V8 CH-1273